Injection Site Reaction clinical trials
The registry lists 22 studies for Injection Site Reaction across 9 countries. 3 are recruiting or about to start. 7 of them are mainly about Injection Site Reaction (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Injection Site Reaction studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Duke University (4) · Suisselle (2) · Biogen (2) · FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE (1) · Holy Name Medical Center, Inc. (1) · Merz North America, Inc. (1) · Bursa Yüksek İhtisas Education and Research Hospital (1) · Mahidol University (1)
What is being tested here
Drugs under test in Injection Site Reaction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cabotegravir | 0 | 0 | 1 |
| Fluzone High-Dose | 0 | 0 | 1 |
| Sodium Chloride | 0 | 0 | 1 |
| ISIS-113715 | 0 | 0 | 1 |
| Peginterferon beta-1a | 0 | 0 | 1 |
| Prednisone | 0 | 0 | 1 |
| Acetaminophen | 0 | 0 | 1 |
| Brimonidine | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Aug 2027Effectiveness and Safety of Cellbooster Glow in Healthy Subjects · Suisselle
- Oct 2027Effectiveness and Safety of Cellbooster Hair in Healthy Subjects · Suisselle
Who these studies take
Of the 1 Injection Site Reaction studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 0 (0%) | 0 (0%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 22 studies, recruiting or not: 36% stop at 75 or younger and 36% at 65; 14% take children; 0% are for women only and 5% for men only; 55% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered2
- Effectiveness and Safety of Cellbooster Hair in Healthy SubjectsNov 10, 2026NCT07929857
- Effectiveness and Safety of Cellbooster Glow in Healthy SubjectsNov 10, 2026NCT07929870
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- Effectiveness and Safety of Cellbooster Glow in Healthy SubjectsNot yet recruitingNCT07929870Not applicable1 country
- Effectiveness and Safety of Cellbooster Hair in Healthy SubjectsNot yet recruitingNCT07929857Not applicable1 country
- Naldebain and Video-assisted Thoracoscopic SurgeryRecruitingNCT04962152Phase 41 country
- Prospective Study to Assess Tissue Responses After Injection With Biostimulatory ProductsCompletedNCT06093815Not applicable1 country
- Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.Active, not recruitingNCT077037481 country
- Safety of Pediatric COVID-19 VaccinationCompletedNCT051571911 country
- A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIVActive, not recruitingNCT06970223Phase 11 country
- Simultaneous RZV and aIIV4 VaccinationCompletedNCT05007041Phase 41 country
- Simultaneous mRNA COVID-19 and IIV4 Vaccination StudyCompletedNCT05028361Phase 41 country
- Sorrel 25R Injector - Sorrel Clinical Study ProtocolStatus unknownNCT05221333Not applicable1 country
- Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 VaccinationCompletedNCT05157230Not applicable1 country
- FLUAD® vs. Fluzone® High-Dose StudyCompletedNCT03183908Phase 41 country
- Can Epinephrine Coated Syringe for Subcutaneous Immunotherapy (SCIT) Reduce Large Local Reaction?CompletedNCT03963115Phase 1/21 country
- A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple SclerosisCompletedNCT033473701 country
- Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side EffectsStatus unknownNCT03424733Phase 41 country
- A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.CompletedNCT03841396Phase 4
- Effectiveness of Mechano-Analgesia and Cold Application on Ecchymosis, Pain and Satisfaction at Subcutaneous Heparin InjectionCompletedNCT03645369Not applicable
- Brimonidine Tartrate for the Treatment of Injection Related ErythemaWithdrawnNCT02568111Phase 4
- Transgender, Silicone and Blood SmearCompletedNCT025807601 country
- Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon AdministrationCompletedNCT00333736Phase 21 country
- Study to Evaluate the Need of Needle Change for Application of Intramuscular, Subcutaneous and Intradermal Injection.CompletedNCT01271608Not applicable1 country
- Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715CompletedNCT00365781Phase 11 country